Hepatitis C in Renal Transplant Recipients

Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.

The aim of the present trial is to evaluate whether the conversion of immunosuppression from tacrolimus to cyclosporine A induces changes in (i) hepatitis C-virus load, (ii) parameters of hepatic function and (iii) parameters of glucose tolerance in hepatitis C-positive renal transplant recipients.

Inclusion Criteria:

• written informed consent
• prior renal transplantation
• current tacrolimus-based immunosuppressive regimen
• hepatitis C-infection
• age 18-70 years

Exclusion Criteria:

• current hemodialysis or peritoneal dialysis
• pregnancy or breastfeeding
• known contraindication for cyclosporine A-treatment